Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced today that its clinical facility in Mexico City has begun recruiting patients for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens designed to potentially eliminate the need for corrective lenses.
The Group Two study marks a significant advancement from the initial safety-focused Group One trial. While Group One concentrated exclusively on safety, the upcoming surgeries will evaluate both safety and visual performance, specifically near and distance vision, according to the company. This shift underscores the progression of Ocumetics' clinical development program as it moves toward a product that could offer patients clear vision at all distances without glasses or contact lenses.
Patient recruitment is underway at the same Mexico City facility that successfully conducted Group One surgeries in Fall 2025. The company targets surgeries for Fall 2026, with Dean Burns, President and CEO of Ocumetics, expressing enthusiasm: "We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter."
Group Two participants will receive the latest-generation Ocumetics Lens, which incorporates advanced design improvements, and the lens will be implanted using the company's enhanced delivery system. This combination is part of Ocumetics' strategy to refine its technology and deliver a differentiated solution for patients seeking improved vision across a broader range of distances.
The announcement also highlights an upcoming data milestone: Group One patients are approaching their 12-month follow-up visits, which will provide longer-term clinical data on the lens's safety, performance, and handling. The company reported that Group One outcomes met and exceeded expectations, providing crucial information that has informed the design and conduct of the Group Two study.
The implications of this development are substantial for the ophthalmology industry. If the Ocumetics Lens proves successful in clinical trials, it could represent a paradigm shift in cataract and refractive surgery. Unlike traditional monofocal or multifocal intraocular lenses, the Ocumetics Lens is designed to mimic the eye's natural focusing ability by using the eye's own muscles to shift focus from distance to near, potentially offering seamless vision without the aid of glasses.
For patients, this could mean a reduced dependence on corrective eyewear after cataract surgery or refractive lens exchange. For the ophthalmic industry, a successful accommodating lens could disrupt the current market, which heavily relies on glasses, contact lenses, and laser procedures. However, it is important to note that the product is still in the early feasibility study phase, and regulatory approvals are not yet in place.
The Group Two study results, along with the 12-month data from Group One, will be critical in determining the next steps for Ocumetics' clinical program. The company's commitment to advancing this technology is evident in its statement: "This combination represents the continued evolution of our technology and our commitment to developing a truly differentiated solution for patients seeking improved vision across a broader range of distances."
Ocumetics is a Canadian research and product development company focused on advanced vision correction solutions. Its intraocular lens fits within the eye's natural lens compartment and is designed to allow the eye's natural muscle activity to shift focus, potentially eliminating the need for corrective lenses. As the company moves forward, the ophthalmic community will be watching closely for the outcomes of these next clinical trials.
